Anti-Mouse LPAM-1 - PE

LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow progenitor cells.

0.2 mg/ml

R-phycoerythrin (PE)

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

TK1 Cells

LPAM-1 antibody, clone DATK32, recognizes mouse lymphocyte Peyer?s patch adhesion molecule (LPAM-1), also known as integrin alpha 4 beta 7 (α4β7). LPAM-1 is a heterodimer of the 154 kDa integrin α4 (CD49d) and 130 kDa integrin β7 chains and is a member of the Ig superfamily. LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow hematopoietic stem cells1,2. LPAM-1 mediates adhesion to endothelial cells, promoting leukocyte transmigration across high endothelial venules (HEVs) during the inflammatory response. LPAM-1 binds to several ligands, including vascular adhesion molecule-1 (VCAM-1/CD106), mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and fibronectin. MAdCAM-1 is expressed exclusively on endothelial cells of the gut and gut-associated lymphoid tissues, such as Peyer?s patches (PPs), and binding of LPAM-1 to MAdCAM-1 contributes to lymphocyte homing to mucosal tissues3,4. Vedolizumab, an anti-LPAM-1 monoclonal antibody, is approved to treat inflammatory bowel disease and effectively induces and maintains remission in Crohn's disease and ulcerative colitis5-8.

311144

Integrin α4β7